Burning Rock Biotech (BNR) Debt to Equity: 2019-2025
Historic Debt to Equity for Burning Rock Biotech (BNR) over the last 5 years, with Sep 2025 value amounting to $1.7 million.
- Burning Rock Biotech's Debt to Equity rose 110.08% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $59.2 million, marking a year-over-year increase of 290.81%. This contributed to the annual value of -$12,748 for FY2024, which is 70.81% up from last year.
- Latest data reveals that Burning Rock Biotech reported Debt to Equity of $1.7 million as of Q3 2025, which was up 69,294,203,900.00% from $0.00 recorded in Q2 2025.
- In the past 5 years, Burning Rock Biotech's Debt to Equity registered a high of $141.4 million during Q4 2024, and its lowest value of -$288.5 million during Q3 2023.
- Moreover, its 3-year median value for Debt to Equity was -$5.7 million (2024), whereas its average is -$26.4 million.
- As far as peak fluctuations go, Burning Rock Biotech's Debt to Equity surged by 168,589,838,988.43% in 2021, and later slumped by 5,799,164,113,003.23% in 2022.
- Quarterly analysis of 5 years shows Burning Rock Biotech's Debt to Equity stood at $0.00 in 2021, then tumbled by 5,799,164,113,003.23% to -$74.5 million in 2022, then skyrocketed by 95.93% to -$3.0 million in 2023, then skyrocketed by 4,760.94% to $141.4 million in 2024, then spiked by 110.08% to $1.7 million in 2025.
- Its Debt to Equity stands at $1.7 million for Q3 2025, versus $0.00 for Q2 2025 and $141.4 million for Q4 2024.